الفهرس 
: An Overview into the clinicial presentation and diagnosis of COVID-19 in ESRD and normal populationOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Abstract
Background. End-stage renal disease (ESRD) patients on maintenance hemodialysis (MHD) are highly vulnerable to severe manifestations of COVID-19 as increased risk of thromboembolic disease and worsened neuropsychiatric status.
Aim. To assess the long-term thrombotic and neuropsychiatric sequelae of SARS-CoV-2 in post-COVID-19 ESRD patients on MHD.
Patients and Methods. We followed for 12 months, 35 clinically stable HD patients on MHD who were confirmed or highly suspected for COVID-19 by positive SARS-CoV-2 RT-PCR and/or high probability on HRCT chest imaging. We recorded demographics, HD and COVID-19 related data, thromboembolic history, and psychiatric history. We recorded baseline and follow-up CBC with differential counts, D-dimer, PT, INR, and HRCT chest findings. We assessed post-COVID-19 neuropsychiatric sequelae using the arabic versions of Hamilton’s depression rating scale (HAM-D) and Taylor’s manifest anxiety Scale (TMAS).
Results. TLC, Lymphocytes and Platelets were significantly lower during infection than pre-infection, six months, and one-year post-infection ([P<0.001], [P=0.003], [P=0.014], respectively). Six months after infection, d-dimer levels were higher than normal values. The incidence of vascular access thrombosis was (25.7%). The scores of HAM-D and TMAS were high (25 [IQR; 17–28]) and (26 [IQR; 19-33]), respectively and the prevalence of depression and anxiety symptoms were 94.3% and 85.7%, respectively.
Conclusions. During infection, ESRD patients showed significantly lower TLC, lymphocytes, and platelets than pre-infection, six months, and one-year post-infection. They had high levels of d-dimer six months post-infection and a high risk for vascular access thrombosis. Their psychological wellbeing was markedly impaired by the pandemic resulting in depression and anxiety